Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Rogers

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association|December 13, 2016
Parental influence on driver licensure in adolescence: A randomized controlled trialJessica H Mirman, Allison E Curry, Flaura K Winston, et al.
Science (New York, N.Y.)|February 3, 2007
Structural and regulatory genes required to make the gas dimethyl sulfide in bacteriaJonathan D Todd, Rachel Rogers, You Guo Li, et al.
Congenital Heart Disease|February 8, 2019
Accuracy of risk prediction scores in pregnant women with congenital heart diseaseYuli Y Kim, Leah A Goldberg, Katherine Awh, et al.
Blood Cancer Journal|October 21, 2024
Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myelomaRakesh Popat, Bradley Augustson, Mercedes Gironella, et al.
MMWR. Morbidity and Mortality Weekly Report|July 26, 2019
Notes from the Field: Targeted Biomonitoring for GenX and Other Per- and Polyfluoroalkyl Substances Following Detection of Drinking Water Contamination - North Carolina, 2018Jamie R Pritchett, Jessica L Rinsky, Beth Dittman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 1, 2018
A Randomized Trial of a Multicomponent Intervention to Promote Medication Adherence: The Teen Adherence in Kidney Transplant Effectiveness of Intervention Trial (TAKE-IT)Bethany J Foster, Ahna L H Pai, Nataliya Zelikovsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2026
Efficacy and Safety of Belantamab Mafodotin with Bortezomib Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: the DREAMM-6 Arm B TrialRakesh Popat, Bradley Augustson, Paul Cannell, et al.
The Lancet. Haematology|July 18, 2025
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trialVania Hungria, Marek Hus, ChengCheng Fu, et al.
Blood Advances|August 5, 2025
Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 TrialsMaria-Victoria Mateos, Suzanne Trudel, Hang Quach, et al.
The Lancet. Oncology|July 18, 2025
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trialVania Hungria, Paweł Robak, Marek Hus, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association|December 13, 2016
Parental influence on driver licensure in adolescence: A randomized controlled trialJessica H Mirman, Allison E Curry, Flaura K Winston, et al.
Science (New York, N.Y.)|February 3, 2007
Structural and regulatory genes required to make the gas dimethyl sulfide in bacteriaJonathan D Todd, Rachel Rogers, You Guo Li, et al.
Congenital Heart Disease|February 8, 2019
Accuracy of risk prediction scores in pregnant women with congenital heart diseaseYuli Y Kim, Leah A Goldberg, Katherine Awh, et al.
Blood Cancer Journal|October 21, 2024
Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myelomaRakesh Popat, Bradley Augustson, Mercedes Gironella, et al.
MMWR. Morbidity and Mortality Weekly Report|July 26, 2019
Notes from the Field: Targeted Biomonitoring for GenX and Other Per- and Polyfluoroalkyl Substances Following Detection of Drinking Water Contamination - North Carolina, 2018Jamie R Pritchett, Jessica L Rinsky, Beth Dittman, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 1, 2018
A Randomized Trial of a Multicomponent Intervention to Promote Medication Adherence: The Teen Adherence in Kidney Transplant Effectiveness of Intervention Trial (TAKE-IT)Bethany J Foster, Ahna L H Pai, Nataliya Zelikovsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2026
Efficacy and Safety of Belantamab Mafodotin with Bortezomib Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: the DREAMM-6 Arm B TrialRakesh Popat, Bradley Augustson, Paul Cannell, et al.
The Lancet. Haematology|July 18, 2025
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trialVania Hungria, Marek Hus, ChengCheng Fu, et al.
Blood Advances|August 5, 2025
Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 TrialsMaria-Victoria Mateos, Suzanne Trudel, Hang Quach, et al.
The Lancet. Oncology|July 18, 2025
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trialVania Hungria, Paweł Robak, Marek Hus, et al.
Pageof 5